Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q3 FY26ended Jun 30, 2026 | Aug 3, 2026 | −$0.56 | −269.7% | $118.38M | +23.2% | −$0.49 |
| Q2 FY26ended Mar 31, 2026 | May 4, 2026 | −$0.71 | — | $110.72M | +19.3% | −$0.54 |
| Q1 FY26ended Dec 31, 2025 | — | −$0.50 | — | $103.70M | +16.9% | — |
| Q4 FY25ended Sep 30, 2025 | — | −$0.45 | — | $99.01M | +16.9% | — |
| Q3 FY25ended Jun 30, 2025 | — | $0.33 | — | $96.06M | +17.9% | — |
| Q2 FY25ended Mar 31, 2025 | — | −$0.66 | — | $92.79M | +23.2% | — |
| Q1 FY25ended Dec 31, 2024 | — | −$0.53 | — | $88.71M | +24.1% | — |
| Q4 FY24ended Sep 30, 2024 | — | −$0.59 | — | $84.71M | +26.5% | — |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Twist Bioscience shares, not any token. As of Aug 3, 2026, from Massive's standardised financials and the earnings calendar.
| Q3 FY24ended Jun 30, 2024 |
| — |
| −$1.47 |
| — |
| $81.46M |
| — |
| — |
| Q2 FY24ended Mar 31, 2024 | — | −$0.79 | — | $75.30M | — | — |
| Q1 FY24ended Dec 31, 2023 | — | −$0.75 | — | $71.50M | — | — |
| Q4 FY23ended Sep 30, 2023 | — | −$0.81 | — | $66.95M | — | — |